This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Loo K , Gauvin G , Soliman I , Renzetti M , Deng M , Ross E , Luo B , Wu H , Reddy S , Olszanski AJ , Farma JM
Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response
Pigment Cell Melanoma Res. 2020 Nov;33(6) :878-888
PMID: 32564504 PMCID: PMC7713701 URL: https://www.ncbi.nlm.nih.gov/pubmed/32564504
AbstractINTRODUCTION: Considerable advances in melanoma have been realized through immunotherapy. The principal aim was to determine whether primary tumor characteristics or next-generation sequencing (NGS) could serve as markers of immunotherapy response. METHODS AND RESULTS: The study cohort consisted of 67 patients who received immunotherapy for recurrent or metastatic melanoma and for whom primary tumor biopsies and pathology reports were available. A subset of 59 patient tumors were profiled using an NGS panel of 50 cancer-related genes. Objective response rate to immunotherapy was assessed using RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. Lymphovascular invasion (LVI) strongly correlated with an increased proportion of immunotherapy responders (p = .002). PFS interval (p = .003) and OS (p = .036) were significantly higher in patients with LVI. NRAS mutation was more strongly correlated with an increased proportion of immunotherapy responders (p =.050). PFS was significantly higher in patients with NRAS mutation (p = .042); no difference in OS (p = .111). DISCUSSION: This analysis demonstrates an association between lymphovascular invasion and immunotherapy response. Additionally, NGS mutation analysis demonstrated a potential association between NRAS mutations and immunotherapy response.
Notes1755-148x Loo, Kimberly Gauvin, Gabrielle Soliman, Iman Renzetti, Madelyn Deng, Mengying Ross, Eric Luo, Biao Wu, Hong Reddy, Sanjay Olszanski, Anthony J Farma, Jeffrey M ORCID: https://orcid.org/0000-0003-2966-9704 Conquer Cancer ASCO Foundation P30 CA006927/BC/NCI NIH HHS/United States Journal Article England Pigment Cell Melanoma Res. 2020 Jun 21. doi: 10.1111/pcmr.12909.